Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10380 in Chinese Adult Patients With Acute Schizophrenia
NCT07550387Phase 2Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obuprazine in schizophrenia, sponsored by Hansoh Pharmaceutical Group. Started May 2024; status: completed.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07550387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550387.